|
rs121913448
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I.
|
15194504 |
2004 |
|
rs1416364034
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I.
|
15194504 |
2004 |
|
rs387906517
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I.
|
15194504 |
2004 |
|
rs121913459
|
|
|
0.100 |
GeneticVariation |
BEFREE |
More importantly, ON012380 was found to induce apoptosis of all of the known imatinib-resistant mutants at concentrations of <10 nM concentration in vitro and cause regression of leukemias induced by i.v. injection of 32Dcl3 cells expressing the imatinib-resistant BCR-ABL isoform T315I.Daily i.v. dosing for up to 3 weeks with a >100 mg/kg concentration of this agent is well tolerated in rodents, without any hematotoxicity.
|
15677719 |
2005 |
|
rs1800562
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Interactions of HFE with environmental and genetic factors, most of which are recognized, may play a role in modification of susceptibility to leu</span>kemia conferred by C282Y.
|
15775751 |
2005 |
|
rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
|
16474404 |
2006 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Homozygous V617F mutation is associated with the clinical picture of classic PV and with a higher tendency to secondary myelofibrosis, but with no increased leukemia unless other biological or genetic factors come into play, such as myelosuppressive agents or the acquisition of additional biologic or genetic defects.
|
16810614 |
2006 |
|
rs1800562
|
|
|
0.030 |
GeneticVariation |
BEFREE |
HFE-codon 63/282 (H63D/C282Y) gene variants in Mexican Mestizos are not risk factors for leukemia.
|
16314188 |
2006 |
|
rs397507444
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our investigation provides interesting data concerning the opposite effect of A1298C polymorphisms, particularly in the light of relatively scarce data regarding the MTHFR role in leukemia susceptibility in different populations.
|
16182363 |
2006 |
|
rs1799945
|
|
|
0.010 |
GeneticVariation |
BEFREE |
HFE-codon 63/282 (H63D/C282Y) gene variants in Mexican Mestizos are not risk factors for leukemia.
|
16314188 |
2006 |
|
rs35602083
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data suggest that the FLT3 D324N variant might be associated with a predisposition to different subtypes of leukemia.
|
16320249 |
2006 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01).
|
17229652 |
2007 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
|
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In attempting to establish a murine model of human KIT(D816V) (hKIT(D816V))-mediated leukemia, we uncovered an unexpected relationship between cellular transformation and intracellular trafficking.
|
17060458 |
2007 |
|
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In attempting to establish a murine model of human KIT(D816V) (hKIT(D816V))-mediated leukemia, we uncovered an unexpected relationship between cellular transformation and intracellular trafficking.
|
17060458 |
2007 |
|
rs387906659
|
|
|
0.020 |
GeneticVariation |
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
|
rs397507476
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
18042262 |
2008 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
|
17395259 |
2008 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
|
18665177 |
2008 |
|
rs121434592
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The E17K change results in constitutive AKT1 activation and induces leukaemia in mice.
|
18504432 |
2008 |
|
rs61754966
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Among these, an association with cancer was found most frequently for 657del5 (in leukemia/lymphoma and breast cancer) and I171V (in leukemia, breast, head and neck and colorectal cancers); however, other studies gave contradictory results.
|
18606567 |
2008 |
|
rs61754966
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Positive associations have also been reported for leukaemia and larynx cancer suggesting that I171V could be a more general susceptibility factor for malignancies.
|
18049891 |
2008 |
|
rs387906659
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
|
18665177 |
2008 |
|
rs10065633
|
|
|
0.010 |
GeneticVariation |
BEFREE |
All three htSNPs showed correlation with blood infection levels in malaria patients, and the rs10065633 polymorphism was associated with severe disease (P=0.02).
|
18200030 |
2008 |
|
rs121913488
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.
|
18230792 |
2008 |